Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2007.0056



Preventing CDH1 Mutation Carriers
Theodore Liakakos, M.D.

Prognosis of gastric cancer in the West is poor with an overall 5-year survival rate of only 23% in the U.S.A. [1]. Although high survival rates are reported with adequate local therapy (surgery ) in early-stages gastric adenocarcinoma [2,3] or lymphoma [4], most patients in the West have a late diagnosis in advanced tumor stages with poor outcomes. Despite adequate locoregional tumor control with standardized, Japanese-type D2/D3 lymphadenectomy [2,5-8] or limited D1 surgery plus chemoradiation [9,10] and modest efficacy of adjuvant chemotherapy [11], recurrence and survival rates are disappointing [1].

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004